MedTrace Logo

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

NCT04534270 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-06-21

No results posted yet for this study

Summary

The purpose of the study is to investigate the antiproteinuric effect of Dapagliflozin in children with proteinuria.

Conditions

  • Proteinuria

Interventions

DRUG

Dapagliflozin

Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks

Sponsors & Collaborators

  • Children's Hospital of Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-06
Primary Completion
2021-12-30
Completion
2022-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04534270 on ClinicalTrials.gov